sarclisa® (isatuximab) update | paul richardson, md | ims 2022
Published 2 years ago • 575 plays • Length 1:59
Download video MP4
Download video MP3
Similar videos
-
7:32
myeloma determination study | paul richardson, md | ims 2022
-
1:51
celmods® mezigdomide | paul richardson, md | ims 2022
-
8:06
mezigdomide (cc-92480) | paul richardson, md | ash 2022
-
7:26
treatment options for frail patients at early relapse | paul richardson, md | ims 2023
-
5:11
asco 2019: isatuximab icaria-mm trial updates with dr. paul richardson
-
2:47
mezigdomide plus dexamethasone in rrmm: cc-92480-mm-002 trial results| paul richardson, md |ash 2023
-
1:04:18
multiple myeloma mid-year progress with dr. paul richardson of dana farber
-
5:59
bispecific antibodies and precision medicine insights on myeloma px | ola landgren, md | eha 2024
-
7:19
renal insufficiency in multiple myeloma | ravi vij, md, mba | ims 2022
-
5:29
new criteria for defining high risk multiple myeloma | gareth morgan & faith davies | ims 2024
-
2:59
paul richardson, md on melflufen study results - imw 2019
-
8:00
all about sarclisa (isatuximab) #myeloma
-
2:54
triplet therapy determination phase 3 trial | paul richardson, md | ash 2023
-
3:36
first-line vs. second-line treatment | matthew leblanc, phd | ims 2022
-
1:03:02
healthtree podcast for multiple myeloma: paul richardson, md, dana farber
-
1:08:15
healthtree podcast for multiple myeloma: paul richardson, md, dana farber
-
1:28:01
myeloma crowd: paul richardson, md, dana farber cancer institute
-
1:28:28
mpatient myeloma radio: dr. paul richardson, md, dana-farber cancer institute
-
5:03
paul richardson: isatuximab improves pfs in relapsed/refractory myeloma
-
3:13
update on the istopmm study | sigurður kristinsson, md, phd | ims 2024
-
4:48
in addition to your myeloma specialist what other healthcare professionals should you consider?
Clip.africa.com - Privacy-policy